out of cancer treatment
To identify the best treatment for recurrent ovarian cancer, researchers at the School of Medicine are studying a technology called the Yale apoptosis assay in combination with another technology called the ChemoFX assay, which could double the response rate to existing drugs.
In patients with recurrent ovarian cancer, it is often difficult to select an effective treatment because the tumor develops resistance to many drugs. Currently, physicians select a drug and must wait about six months to see whether it is effective on a particular patient.
"These two new assays will take the guesswork out of cancer treatment," says lead investigator, Dr. Gil Mor, associate professor of obstetrics and gynecology and reproductive sciences at the School of Medicine. "In patients with very limited time left to live, six months can feel like an eternity when they may have to start a whole new course of treatment if it proves ineffective."
Mor's lab developed the Yale apoptosis assay based on a biological principle that when a drug is effective, it will induce apoptosis (cell death) in the cancer cell. If the cancer cell is resistant to a drug, apoptosis does not occur.
Mor says, "The Yale apoptosis assay will determine whether a drug kills the tumor. The ChemoFX assay will determine whether a drug stops tumor growth. Used together, both assays will distinguish drugs that can stop the growth of the tumor and/or kill the tumor. This was not possible before.
"This test will help physicians predict whether a patient will respond to a specific drug, much like they test bacteria for sensitivity to antibiotics," Mor adds.
The technology will be studied with various cancers, beginning with ovarian cancer. The clinical trial is a multi-center study for validation of the assays. Each assay will be evaluated independently and then in combination. The Yale research team partnered with Precision Therapeutics Inc. (PTI), developers of the ChemoFX assay, and is seeking patients from Yale and surrounding communities and from 10 other sites around the country. PTI exclusively licensed the Yale apoptosis assay from Yale. The Yale clinical trial is led by Dr. Thomas Rutherford, associate professor of gynecology at the School of Medicine.
-- By Karen Peart
T H I S
W E E K ' SS T O R I E S
Campus responds to tsunami disaster with relief efforts
Alumnus' gift will fund environment center in new F&ES building
Fossils offer insights into consequences of extinction
Festival puts spotlight on the arts at Yale
ENDOWED PROFESSORSHIPSDr. Robert Alpern appointed as Ensign Professor of Medicine
Margaret Grey named Goodrich Professor of Nursing Research
Gail Melkus is Independence Foundation Professor of NursingCampus events mark birthday of Martin Luther King Jr.
Astronomers' maps show dark matter clumps in galaxies
With grant, Yale to develop new programs to retain doctoral students
Exhibits feature landscape paintings in era of British exploration
SCHOOL OF MEDICINE NEWSFoundation gives $5 million for Clinical Research Fellowships
New test could take 'guesswork' out of cancer treatment
Researchers discover a key to blocking the body's . . .
Yale Multiple Sclerosis Clinic receives $50,000
Study finds that children's anxiety level before surgery . . .
Study: Delaying hospice care can cause depression in caregiversEngineer wins prestigious Nishizawa Medal
Colloquium honors retired professor Michael Holquist
Artworks based on sacred themes and Ethiopian iconography . . .
Works by 'mythic figure in modern art' are the focus . . .
Exhibit showcases examples of crimes in ancient history
Evolution is theme of scientist's Terry Lectures
Himalayan kingdom is topic of next Tetelman Lecture
Statue honors accomplishments of Yale's first Chinese student
World Conservation Union adopts resolution by F&ES students
In Memoriam: Dr. Nicholas M. Greene
Campus Notes
Bulletin Home|Visiting on Campus|Calendar of Events|In the News
Bulletin Board|Classified Ads|Search Archives|Deadlines
Bulletin Staff|Public Affairs|News Releases|
E-Mail Us|Yale Home